O crescimento da população idosa vem motivando mudanças nos modelos assistenciais buscando incorporar a identificação, avaliação e tratamento de idosos com perfis mórbidos e funcionais variados. O objetivo do artigo foi identificar o Risco de Internação Hospitalar (RIH) em idosos do município de Porto Alegre. O estudo foi do tipo transversal quantitativo descritivo, por meio da aplicação de questionário de triagem de RIH previamente validado. A amostra foi composta por 80 idosos com idade de 65 anos ou mais, residentes em dois setores censitários na área adscrita de uma Unidade Básica de Saúde. Calculou-se o RIH através de análise de regressão logística sendo classificado em estratos baixo, médio, médio-alto e alto. Identificou-se maior prevalência dos estratos de RIH baixo 47,5% (n = 38) e médio 20% (n = 16). Os resultados desta pesquisa indicam a necessidade de integrar a prevenção de agravo e promoção de saúde no planejamento em saúde a fim de atingir a assistência adequada ao idoso.
OBJECTIVES:Anemia is a common complication among chronic kidney disease patients on hemodialysis, occurring mostly due to erythropoietin deficiency. This randomized noninferiority trial sought to compare the efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos, a biologics manufacturer affiliated with the Brazilian government, with those of a commercially available product currently used in Brazil (a biosimilar epoetin formulation).METHODS:The sample size needed to enable demonstration of noninferiority with a statistical power of 85% for a between-group difference in hemoglobin levels of no more than 1.5 g/dL was calculated. In total, 74 patients were randomly assigned to receive the epoetin formulation from Bio-Manguinhos (n = 36) or the biosimilar epoetin formulation (n = 38) in a double-blind fashion. The inclusion criteria were current epoetin therapy and stable hemoglobin levels for at least 3 months prior to the study. The primary and secondary outcomes were mean monthly hemoglobin levels and safety, respectively. The dose was calculated according to international criteria and adjusted monthly in both groups according to hemoglobin levels and at the assistant physicians' discretion. Iron storage was estimated at baseline and once monthly. Clinicaltrials.gov: NCT01184495.RESULTS:The study was conducted for 6 months after randomization. The mean baseline hemoglobin levels were 10.9±1.2 and 10.96±1.2 g/dL (p = 0.89) in the Bio-Manguinhos epoetin and biosimilar epoetin groups, respectively. During the study period, there was no significant change in hemoglobin levels in either group (p = 0.055, ANOVA). The epoetin from Bio-Manguinhos was slightly superior in the last 3 months of follow-up. The adverse event profiles of the two formulations were also similar.CONCLUSIONS:The epoetin formulations tested in this study are equivalent in efficacy and safety.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.